Finance

Beta
Lists
IBAB:EBR
Ion Beam Applications SA
€17.10
+1.18%
(+0.20) 1D
Jun 10, 5:35:18 PM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for IBAB...
Open
€16.70
High
€17.10
Low
€16.52
Mkt. cap
505.14M
Avg. vol.
36.04K
Volume
35.73K
P/E ratio
40.69
52-wk high
€17.18
52-wk low
€9.90
EPS
€0.42
Shares outstanding
30.28M
No. of employees
2K
Open
€16.70
High
€17.10
Low
€16.52
Mkt. cap
505.14M
Avg. vol.
36.04K
Volume
35.73K
P/E ratio
40.69
52-wk high
€17.18
52-wk low
€9.90
EPS
€0.42
Shares outstanding
30.28M
No. of employees
2K
Analyst outlook
Analyst Ratings
Based on 1 analyst giving stock ratings to IBAB in the past 3 months
Hold
Buy
0
Hold
1
Sell
0
12 month forecast
Based on 1 Wall Street analyst offering 12 month price targets for IBAB in the last 3 months.
Highest
Current €17.10
€12.00 (-29.82%)
Average
€12.00 (-29.82%)
Lowest
€12.00 (-29.82%)
News stories
From sources across the web
www.marketscreener.com
www.marketscreener.com
·
2 days ago
IBA – ACQUISITION OF OWN SHARES
Profile
IBA is a medical technology company based in Louvain-la-Neuve. The company was founded in 1986 by Yves Jongen within the Cyclotron Research Center of the University of Louvain and became a university spin-off. It employs about 1500 people in 40 locations. The company developed cyclotrons and integrated proton therapy centers is active in the field of proton therapy, dosimetry, radiopharmacy solutions and industrial sterilisation. IBA installed its first proton therapy equipment for Boston's Massachusetts General Hospital in 2001, and for University of Pennsylvania's Proton Center in 2009. It supplied equipment and services to Proton Partners International which was developing three proton beam therapy centers in the United Kingdom. In 2017, IBA invested €16 million in the construction of a new logistics and production center in Louvain-la-Neuve. Wikipedia
About Ion Beam Applications SA
CEOOlivier Legrain
Employees2.04K
Founded1986
Headquarters-
SectorMedical device
Websiteiba-worldwide.com
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
152.45M
152.45M
157.64M
157.64M
Cost of goods sold
107.45M
107.45M
102.83M
102.83M
Cost of revenue
107.45M
107.45M
102.83M
102.83M
Research and development expenses
15.60M
15.60M
15.48M
15.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
24.10M
24.10M
30.94M
30.94M
Operating expense
41.50M
41.50M
40.94M
40.94M
Total operating expenses
148.95M
148.95M
143.77M
143.77M
Operating income
3.50M
3.50M
13.86M
13.86M
Other non operating income
-
-
-1.29M
-1.29M
EBT including unusual items
600.00K
600.00K
8.78M
8.78M
EBT excluding unusual items
600.00K
600.00K
13.05M
13.05M
Income tax expense
1.90M
1.90M
1.12M
1.12M
Effective tax rate
316.67%
316.67%
12.73%
12.73%
Other operating expenses
1.80M
1.80M
-5.83M
-5.83M
Net income
-1.30M
-1.30M
7.67M
7.67M
Net profit margin
-0.85%
-0.85%
4.86%
4.86%
Earnings per share
-
-
-
-
Interest and investment income
-
-
2.13M
2.13M
Interest expense
-2.50M
-2.50M
-
-
Net interest expenses
-2.50M
-2.50M
2.13M
2.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
6.70M
6.70M
15.80M
15.17M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer